📊 CRSP Key Takeaways
Investment Thesis
CRSP is a pre-commercial stage biotech company burning significant cash with minimal revenue, posting operating losses exceeding $664M and free cash flow of -$346M. While the company maintains a strong balance sheet with $347.6M in cash and minimal debt, the 90.6% revenue collapse and massive operating losses indicate the business is not yet generating sustainable economic value. At current cash burn rates, the company has limited runway before requiring additional financing or demonstrating meaningful clinical/commercial progress.
CRSP Strengths
- Strong balance sheet with $1.9B stockholders equity and no meaningful long-term debt
- Adequate liquidity with $347.6M cash and 13.32x current ratio
- Significant insider activity with 13 Form 4 filings indicating management engagement
CRSP Risks
- Severe cash burn of $345M in operating cash flow with negative free cash flow of -$346M
- Revenue collapsed 90.6% YoY to just $3.5M, indicating loss of major revenue source or milestone delays
- Operating losses of $664.6M and net losses of $581.6M demonstrate pre-commercial stage business model with no clear path to profitability
Key Metrics to Watch
- Quarterly cash burn rate and cash runway extension
- Clinical trial progress and regulatory milestones for pipeline programs
- Revenue stabilization and growth from existing or new partnerships/programs
CRSP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.32x current ratio provides a solid financial cushion.
CRSP Profitability Ratios
CRSP vs Healthcare Sector
How CRISPR Therapeutics AG compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRSP Balance Sheet & Liquidity
CRSP 5-Year Financial Trend
5-Year Trend Summary: CRISPR Therapeutics AG's revenue has declined by 59% over the 5-year period, indicating business contraction. The most recent EPS of $-1.94 indicates the company is currently unprofitable.
CRSP Growth Metrics (YoY)
CRSP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $602.0K | -$85.9M | $-1.01 |
| Q2 2025 | $517.0K | -$116.6M | $-1.49 |
| Q1 2025 | $504.0K | -$116.6M | $-1.43 |
| Q3 2024 | N/A | -$53.1M | $-1.01 |
| Q2 2024 | $517.0K | -$53.1M | $-0.98 |
| Q1 2024 | $504.0K | -$53.1M | $-0.67 |
| Q3 2023 | N/A | -$53.1M | $-1.41 |
| Q2 2023 | $158.0K | -$53.1M | $-0.98 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRSP Capital Allocation
CRSP SEC Filings
Access official SEC EDGAR filings for CRISPR Therapeutics AG (CIK: 0001674416)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRSP
What is the AI rating for CRSP?
CRISPR Therapeutics AG (CRSP) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRSP's key strengths?
Strong balance sheet with $1.9B stockholders equity and no meaningful long-term debt. Adequate liquidity with $347.6M cash and 13.32x current ratio.
What are the risks of investing in CRSP?
Severe cash burn of $345M in operating cash flow with negative free cash flow of -$346M. Revenue collapsed 90.6% YoY to just $3.5M, indicating loss of major revenue source or milestone delays.
What is CRSP's revenue and growth?
CRISPR Therapeutics AG reported revenue of $3.5M.
Does CRSP pay dividends?
CRISPR Therapeutics AG does not currently pay dividends.
Where can I find CRSP SEC filings?
Official SEC filings for CRISPR Therapeutics AG (CIK: 0001674416) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRSP's EPS?
CRISPR Therapeutics AG has a diluted EPS of $-6.47.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.